Pulmonary adverse events following immune checkpoint inhibitors

Medicine and Dentistry

• Immune Checkpoint Inhibitor 100%
• Adverse Event 100%
• Lung Cancer 60%
• Neoplasm 40%
• Immune-Related Adverse Events 40%
• Pulmonary Toxicity 40%
• Organ Systems 20%
• Meta-Analysis 20%
• Recurrent Disease 20%
• Interstitial Lung Disease 20%
• Disease Exacerbation 20%
• Systematic Review 20%
• Cancer Treatment 20%
• Avelumab 20%
• Atezolizumab 20%
• Nivolumab 20%
• Durvalumab 20%
• Pembrolizumab 20%
• Immunotherapy 20%
• CTLA-4 20%
• Drug Toxicity 20%
• Programmed Death-Ligand 1 20%
• Immunomodulation 20%
• Ipilimumab 20%
• T Lymphocyte Antigen 20%
• Ticilimumab 20%
• Advanced Cancer 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Immune Checkpoint Inhibitor 100%
• Adverse Event 100%
• Lung Cancer 60%
• Lung Toxicity 40%
• Neoplasm 40%
• Chemotherapy 20%
• Pembrolizumab 20%
• Durvalumab 20%
• Atezolizumab 20%
• Nivolumab 20%
• Avelumab 20%
• Drug Toxicity 20%
• Tremelimumab 20%
• Malignant Neoplasm 20%
• Inflammation 20%
• Disease Exacerbation 20%
• Interstitial Lung Disease 20%
• Immunotherapy 20%
• Recurrent Disease 20%
• Advanced Cancer 20%
• Cytotoxic T Lymphocyte Antigen 4 20%